1Kahramanmaras Necip Fazil City Hospital, Clinic of Medical Oncology, Kahramanmaras, Turkey
2Izmir Katip Celebi University, Ataturk Training and Research Hospital, Department of Medical Oncology, Izmir, Turkey
3Izmir Demokrasi University, Faculty of Medicine, Department of Medical Oncology, Izmir, Turkey
4Izmir Bozyaka Training and Research Hospital, Department of Medical Oncology, Izmir, Turkey
5Izmir Dokuz Eylul University, Faculty of Medicine, Department of Medical Oncology, Izmir, Turkey
Copyright © 2020 by authors and Annals of Medical Research Publishing Inc.
Aim: Oral etoposide dosage is roughly 50-100 mg/m2 on days 1 to 21 every 28 days. However, dosage of 50 mg/day oral etoposide for five days a week is not well published. The present study, aimed to evaluate the efficacy and toxicity profile of low dose oral etoposide regimen (50 mg/day on days 1 to 5 every week) in platinum-resistant epithelial ovarian cancer (EOC).
Material and Methods: This study retrospectively evaluates patients with pathologically confirmed platinum-resistant EOC who were unable to tolerate the standard oral etoposide regimen and were on low dose (d1-5/7) oral etoposide regimen in third line or beyond within the period between 2006 and 2014.
Results: The overall response rate among 33 EOC patients was 15.1% while clinical benefit rate was 42.4% (stable disease in 27.3% and partial response in 15.1%). Median progression-free survival was 4 months (95% confidence interval [CI], 2.8–5.1 months) and median overall survival was 12 months (95% CI, 8.8–15.1 months).
Conclusion: We concluded that low dose oral etoposide (50 mg/day, on days 1 to 5 every week) was effective and well tolerated for platinum-resistant EOC.
Keywords: Epithelial ovarian cancer; oral etoposide; recurrence